Breast Cancer in the Modern Era: A Comprehensive Review on Advances in Understanding and Managing Breast Cancer
DOI:
https://doi.org/10.70749/ijbr.v3i6.1406Keywords:
Breast Cancer, Oncology, Cancer Treatment, Estrogen Receptor, Chemotherapy, ImmunotherapyAbstract
Even with advances in screening and prevention methods, breast cancer is more often diagnosed in women than any other malignancy. An increased knowledge of genetics made it possible for researchers to sort breast cancer into four types: luminal A, luminal B, HER2‑enriched, and triple‑negative, all marked by specific biomarkers and estimations for the outcome. High‑throughput genomic classifiers such as the Breast Cancer Classifier (BCC) have allowed doctors to more accurately choose the best medicine for HER2‑low tumors. Now, liquid biopsies and multiplex immunofluorescence tests are being used, in addition to imaging and samples taken from tissue, to help recognize minimal amounts of disease at an early stage. Among hormone receptor‑positive and BRCA‑mutant patients, CDK4/6 inhibitors, antibody–drug conjugates, and PARP inhibitors have improved progression‑free survival. Tools powered by artificial intelligence are regularly being included in the work of many health professionals, helping them detect diseases more accurately and measure a patient’s probability of illness. However, because some cancer treatments can cause serious side effects in young people and early menopause, efforts are being made to trial new therapies that focus clearly on how these patients feel after surviving cancer. There is a need to explore how neoadjuvant therapy can be improved, use different kinds of data for assessing treatment needs, and ensure that all patients receive the best treatment available. The current review aimed to investigate advances in understanding and managing breast cancer.
Downloads
References
Wilkinson, L. and T. Gathani, Understanding breast cancer as a global health concern. The British journal of radiology, 2022. 95(1130): p. 20211033.
https://doi.org/10.1259/bjr.20211033
GÜLTEKİN, M., et al., World Health Organization call for action to eliminate cervical cancer globally. 2020.
https://doi.org/10.1136/ijgc-2020-001285
Crosby, D., et al., Early detection of cancer. Science, 2022. 375(6586): p. eaay9040.
https://doi.org/10.1126/science.aay9040
Afaya, A., et al., Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review. BMC Health Services Research, 2022. 22(1): p. 1601.
https://doi.org/10.1186/s12913-022-08927-x
Jan, S., et al., Action to address the household economic burden of non-communicable diseases. The Lancet, 2018. 391(10134): p. 2047-2058.
https://doi.org/10.1016/s0140-6736(18)30323-4
Hanna, T.P., et al., Mortality due to cancer treatment delay: systematic review and meta-analysis. bmj, 2020. 371.
https://doi.org/10.1136/bmj.m4087
Milosevic, M., et al., Early diagnosis and detection of breast cancer. Technology and Health Care, 2018. 26(4): p. 729-759.
https://doi.org/10.3233/thc-181277
Zubair, M., S. Wang, and N. Ali, Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology, 2021. 11: p. 632079.
https://doi.org/10.3389/fphar.2020.632079
Barzaman, K., et al., Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology, 2020. 84: p. 106535.
https://doi.org/10.1016/j.intimp.2020.106535
Jeibouei, S., et al., Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics and personalized medicine, 2019: p. 59-73.
https://doi.org/10.2147/pgpm.s167886
Olivier, T. and V. Prasad, Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC medicine, 2022. 20(1): p. 392.
Bickler, S.W., et al., Urbanization in sub-Saharan Africa: declining rates of chronic and recurrent infection and their possible role in the origins of non-communicable diseases. World journal of surgery, 2018. 42: p. 1617-1628.
Kashyap, D., et al., [Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed research international, 2022. 2022(1): p. 9605439.
https://doi.org/10.1155/2022/9605439
Chen, Z., et al., Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017. Breast cancer research and treatment, 2020. 180: p. 481-490.
Birnbaum, J.K., et al., Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. The Lancet Global Health, 2018. 6(8): p. e885-e893.
Orrantia-Borunda, E., et al., Subtypes of breast cancer. Breast Cancer [Internet], 2022.
https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
Schlamadinger, D. Understanding the Molecular Subtypes of Breast Cancer. 2025 [cited 2025;
https://www.bcrf.org/about-breast-cancer/molecular-subtypes-breast-cancer.
Mir, M.A. and H. Qayoom, Introduction to breast cancer, in Therapeutic potential of cell cycle kinases in breast cancer. 2023, Springer. p. 1-22.
Yam, C., S.A. Mani, and S.L. Moulder, Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field. The oncologist, 2017. 22(9): p. 1086-1093.
Mohammed, A.A., H. Rashied, and F.M. Elsayed, CDK4/6 inhibitors in advanced breast cancer, what is beyond? Oncology Reviews, 2019. 13(2): p. 416.
https://doi.org/10.4081/oncol.2019.416
Wang, X., et al., Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Therapy, 2024. 31(9): p. 1283-1291.
Endo, Y., et al., Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. Antibody therapeutics, 2021. 4(1): p. 55-59.
Hurvitz, S.A., et al., Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet, 2023. 401(10371): p. 105-117.
https://doi.org/10.1016/s0140-6736(22)02420-5
Marhold, M., Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer. memo-Magazine of European Medical Oncology, 2022. 15(2): p. 129-132.
Chai, Y., et al., Homologous recombination deficiency (HRD) and BRCA 1/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): A systematic review and meta-analysis. Journal of Personalized Medicine, 2022. 12(2): p. 323.
Hiatt, R.A. and J.G. Brody, Environmental determinants of breast cancer. Annual review of public health, 2018. 39(1): p. 113-133.
https://doi.org/10.1146/annurev-publhealth-040617-014101
Sadeghi, F., et al., Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: Review of radiosensitivity assays. Biological procedures online, 2020. 22: p. 1-28.
CHEK, N. and R.D. RAD51C, GERMLINE GENETIC TESTING FOR GENE VARIANTS ASSOCIATED WITH BREAST CANCER IN INDIVIDUALS AT MODERATE AND HIGH BREAST CANCER RISK (EG, CHEK2, ATM, BARD1, ETC.).
Feng, Y., et al., Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & diseases, 2018. 5(2): p. 77-106.
https://doi.org/10.1016/j.gendis.2018.05.001
Sinha, I., et al., Association between age at menarche and age at menopause among women of an indigenous population of North Bengal, India. Journal of biosocial science, 2021. 53(3): p. 319-335.
Mohanty, S.S. and P.K. Mohanty, Obesity as potential breast cancer risk factor for postmenopausal women. Genes & diseases, 2021. 8(2): p. 117-123.
Kothari, C., C. Diorio, and F. Durocher, The importance of breast adipose tissue in breast cancer. International journal of molecular sciences, 2020. 21(16): p. 5760.
Zakhari, S. and J.B. Hoek, Epidemiology of moderate alcohol consumption and breast cancer: Association or causation? Cancers, 2018. 10(10): p. 349.
https://doi.org/10.3390/cancers10100349
Eve, L., et al., Exposure to endocrine disrupting chemicals and risk of breast cancer. International Journal of Molecular Sciences, 2020. 21(23): p. 9139.
Pashayan, N., et al., Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature reviews Clinical oncology, 2020. 17(11): p. 687-705.
Sareyeldin, R.M., et al., Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancers, 2019. 11(5): p. 646.
https://doi.org/10.3390/cancers11050646
Dauphine, C., et al., Single hormone receptor-positive breast cancers have distinct characteristics and survival. Annals of surgical oncology, 2020. 27: p. 4687-4694.
O'Shaughnessy, J., et al., Risk of recurrence in patients with HER2+ early-stage breast cancer: Literature analysis of patient and disease characteristics. Clinical breast cancer, 2023. 23(4): p. 350-362.
Kreutzfeldt, J., et al., The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. American journal of cancer research, 2020. 10(4): p. 1045.
Godet, I. and D.M. Gilkes, BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integrative cancer science and therapeutics, 2017. 4(1).
https://doi.org/10.15761/icst.1000228
Yousef, A.J.A. Male breast cancer: epidemiology and risk factors. in Seminars in oncology. 2017. Elsevier.
Baglia, M.L., et al., Family history and risk of second primary breast cancer after in situ breast carcinoma. Cancer Epidemiology, Biomarkers & Prevention, 2018. 27(3): p. 315-320.
Azzollini, J., L. Fontana, and S. Manoukian, Hereditary Breast Cancer: BRCA and Other Susceptibility Genes. Breast MRI for High-risk Screening, 2020: p. 23-41.
Grimmett, C., et al., Development of breast cancer choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. Supportive Care in Cancer, 2019. 27: p. 297-309.
https://doi.org/10.1007/s00520-018-4307-x
Zuraidah, E., et al., Correlation between Age at First Menarche and Breast Cancer in Dr. Cipto Mangunkusumo National General Hospital Jakarta in 2010-2014. Asian Pacific Journal of Cancer Care, 2023. 8(3): p. 459-464.
Dunneram, Y., D.C. Greenwood, and J.E. Cade, Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proceedings of the Nutrition Society, 2019. 78(3): p. 438-448.
Bhardwaj, P., et al., Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. The Journal of steroid biochemistry and molecular biology, 2019. 189: p. 161-170.
Vigneswaran, K. and H. Hamoda, Hormone replacement therapy–Current recommendations. Best practice & research Clinical obstetrics & gynaecology, 2022. 81: p. 8-21.
https://doi.org/10.1016/j.bpobgyn.2021.12.001
Vaz-Luis, I. and A.H. Partridge, Exogenous reproductive hormone use in breast cancer survivors and previvors. Nature reviews Clinical oncology, 2018. 15(4): p. 249-261.
Starek-Świechowicz, B., B. Budziszewska, and A. Starek, Endogenous estrogens—breast cancer and chemoprevention. Pharmacological Reports, 2021. 73(6): p. 1497-1512.
Orlandella, F.M., et al., Dissecting the molecular pathways involved in the effects of physical activity on breast cancers cells: a narrative review. Life sciences, 2021. 265: p. 118790.
Dhuli, K., et al., Physical activity for health. Journal of preventive medicine and hygiene, 2022. 63(2 Suppl 3): p. E150.
Linet, M.S., et al., Historical review of occupational exposures and cancer risks in medical radiation workers. Radiation research, 2010. 174(6b): p. 793-808.
https://doi.org/10.1667/rr2014.1
Ng, A.K., et al., Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood, The Journal of the American Society of Hematology, 2002. 100(6): p. 1989-1996.
Lisco, G., et al., Endocrine-disrupting chemicals: introduction to the theme. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2022. 22(7): p. 677-685.
Amir, S., et al., Endocrine disruptors acting on estrogen and androgen pathways cause reproductive disorders through multiple mechanisms: a review. International Journal of Environmental Research and Public Health, 2021. 18(4): p. 1464.
https://doi.org/10.3390/ijerph18041464
Adkins, S., From disposable culture to disposable people: the unintended consequences of plastics. 2018: Wipf and Stock Publishers.
Begum, S., et al., Knowledge, attitude and practice of Bangladeshi women towards breast cancer: a cross sectional study. Mymensingh Med J, 2019. 28(1): p. 96-104.
Sasaki, J., et al., Etiology and management of benign breast disease, in The Breast. 2018, Elsevier. p. 79-92. e5.
Aftab, T., et al., XAI and disease diagnosis, in Explainable Artificial Intelligence (XAI) in Healthcare. 2024, CRC Press. p. 100-140.
https://doi.org/10.1201/9781003426073-8
Barba, D., et al., Breast cancer, screening and diagnostic tools: All you need to know. Critical reviews in oncology/hematology, 2021. 157: p. 103174.
Durur Subaşı, I., Breast imaging for non-radiologists. Erciyes Medical Journal, 2022.
Alzaghal, A.A. and P.J. DiPiro, Applications of advanced breast imaging modalities. Current Oncology Reports, 2018. 20: p. 1-10.
Evans, A., et al., Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights into imaging, 2018. 9: p. 449-461.
https://doi.org/10.1007/s13244-018-0636-z
Houser, M., et al., Current and future directions of breast MRI. Journal of Clinical Medicine, 2021. 10(23): p. 5668.
Mann, R.M., et al., Novel approaches to screening for breast cancer. Radiology, 2020. 297(2): p. 266-285.
Mundinger, A. and M. Hahn, Interventional Radiology. Breast Cancer Essentials: Perspectives for Surgeons, 2021: p. 119-140.
https://doi.org/10.1007/978-3-030-73147-2_13
Lau, H.D., C.S. Kong, and C.S. Kao, Evaluation of diagnostic accuracy and a practical algorithmic approach for the diagnosis of renal masses by FNA. Cancer Cytopathology, 2018. 126(9): p. 782-796.
Geijer, M. and H.A. Domanski, Image-guided fine-needle aspiration cytology. Atlas of fine needle aspiration cytology, 2019: p. 43-55.
https://doi.org/10.1007/978-3-319-76980-6_2
Cil, T.D. and D. McCready, Modern approaches to the surgical management of malignant breast disease: the role of breast conservation, complete mastectomy, skin-and nipple-sparing mastectomy. Clinics in plastic surgery, 2018. 45(1): p. 1-11.
Metere, A., et al., Nipple-sparing mastectomy long-term outcomes: early and late complications. Medicina, 2020. 56(4): p. 166.
Winters, Z.E. and L. Bernaudo, Evaluating the current evidence to support therapeutic mammoplasty or breast-conserving surgery as an alternative to mastectomy in the treatment of multifocal and multicentric breast cancers. Gland Surgery, 2018. 7(6): p. 525.
https://doi.org/10.21037/gs.2018.07.01
Lee, S.B., et al., Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy. Plos one, 2021. 16(5): p. e0251597.
Waks, A.G. and E.P. Winer, Breast cancer treatment: a review. Jama, 2019. 321(3): p. 288-300.
Montemurro, F., I. Nuzzolese, and R. Ponzone, Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert opinion on pharmacotherapy, 2020. 21(9): p. 1071-1082.
Kaššák, F., et al., Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes–past, present and future. The Breast, 2019. 48: p. 73-81.
https://doi.org/10.1016/j.breast.2019.09.008
Lopez-Tarruella, S., et al., How we treat HR-positive, HER2-negative early breast cancer. Future Oncology, 2022. 18(8): p. 1003-1022.
Miranda, F., et al., Resistance to endocrine therapy in HR+ and/or HER2+ breast cancer: the most promising predictive biomarkers. Molecular Biology Reports, 2022. 49(1): p. 717-733.
Roberto, M., et al., CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives. Cancers, 2021. 13(2): p. 332.
Sharma, R., et al., Precision medicine: an optimal approach to patient care in renal cell carcinoma. Frontiers in Medicine, 2022. 9: p. 766869.
https://doi.org/10.3389/fmed.2022.766869
Sarhadi, M., L. Aryan, and M. Zarei, The estrogen receptor and breast cancer: a complete review. CRPASE Trans. Appl. Sci, 2020. 6: p. 309-314.
Pietragalla, A., et al., Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. International Journal of Gynecologic Cancer, 2020. 30(11).
Qian, X., et al., Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast cancer research and treatment, 2020. 179: p. 275-285.
Smith, R.A., et al., Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: a cancer journal for clinicians, 2019. 69(3): p. 184-210.
https://doi.org/10.3322/caac.21557
Conte, L., et al., Breast Cancer Prevention Practices and Knowledge in Italian and Chinese Women in Italy: Clinical Checkups, Free NHS Screening Adherence, and Breast Self-Examination (BSE). Journal of Cancer Education, 2024: p. 1-14.
Hipp, L.E., B.B. Hulswit, and K.J. Milliron, Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk. Best Practice & Research Clinical Obstetrics & Gynaecology, 2022. 82: p. 12-29.
Bissell, M.C., et al., Breast cancer population attributable risk proportions associated with body mass index and breast density by race/ethnicity and menopausal status. Cancer Epidemiology, Biomarkers & Prevention, 2020. 29(10): p. 2048-2056.
https://doi.org/10.1158/1055-9965.epi-20-0358
Sonugür, F.G. and H. Akbulut, The role of tumor microenvironment in genomic instability of malignant tumors. Frontiers in genetics, 2019. 10: p. 1063.
Rezatabar, S., et al., RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. Journal of cellular physiology, 2019. 234(9): p. 14951-14965.
Singh, M., et al., EMT: Mechanisms and therapeutic implications. Pharmacology & therapeutics, 2018. 182: p. 80-94.
Saitoh, M. Transcriptional regulation of EMT transcription factors in cancer. in Seminars in Cancer Biology. 2023. Elsevier.
https://doi.org/10.1016/j.semcancer.2023.10.001
Czekay, R.-P., et al., Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets. Cancers, 2022. 14(5): p. 1231.
Rankin, E.B. and A.J. Giaccia, Cellular microenvironment and metastases, in Abeloff's Clinical Oncology. 2020, Elsevier. p. 47-55. e3.
Tsuchida, J., et al., Clinical target sequencing for precision medicine of breast cancer. International Journal of Clinical Oncology, 2019. 24: p. 131-140.
Mercogliano, M.F., et al., Emerging targeted therapies for HER2-positive breast cancer. Cancers, 2023. 15(7): p. 1987.
https://doi.org/10.3390/cancers15071987
Miziak, P., et al., Estrogen receptor signaling in breast Cancer. Cancers, 2023. 15(19): p. 4689.
Patel, P.S., A. Algouneh, and R. Hakem, Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene, 2021. 40(17): p. 3001-3014.
Collet, L., et al., PARP inhibitors: a major therapeutic option in endocrine-receptor positive breast cancers. Cancers, 2022. 14(3): p. 599.
Uchimiak, K., et al., Current state of knowledge on the immune checkpoint inhibitors in triple-negative breast cancer treatment: approaches, efficacy, and challenges. Clinical Medicine Insights: Oncology, 2022. 16: p. 11795549221099869.
Pereira, M.A., et al., Breast Cancer and Next-Generation Sequencing: Towards Clinical Relevance and Future. Breast Cancer: From Bench to Personalized Medicine, 2022: p. 477-518.
https://doi.org/10.1007/978-981-19-0197-3_20
Li, R.-Y. and Z.-Y. Liang, Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response. Chinese Medical Journal, 2020. 133(20): p. 2476-2485.
https://doi.org/10.1097/cm9.0000000000001097
Zhao, S., et al., Molecular subtypes and precision treatment of triple-negative breast cancer. Annals of translational medicine, 2020. 8(7).
https://doi.org/10.21037/atm.2020.03.194
Wu, H.-J. and P.-Y. Chu, Current and developing liquid biopsy techniques for breast cancer. Cancers, 2022. 14(9): p. 2052.
https://doi.org/10.3390/cancers14092052
Kornecki, A., Current status of contrast enhanced mammography: a comprehensive review. Canadian Association of Radiologists Journal, 2022. 73(1): p. 141-156.
https://doi.org/10.1177/08465371211029047
Galati, F., G. Moffa, and F. Pediconi, Breast imaging: Beyond the detection. European Journal of Radiology, 2022. 146: p. 110051.
https://doi.org/10.1016/j.ejrad.2021.110051
Chang, L., et al., Liquid biopsy in ovarian cancer: Recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics, 2019. 9(14): p. 4130.
https://doi.org/10.7150/thno.34692
Chakrabarti, S., et al., Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (CtDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers, 2022. 14(13): p. 3078.
https://doi.org/10.3390/cancers14133078
Loric, S., et al., Extracellular vesicles in breast cancer: from biology and function to clinical diagnosis and therapeutic management. International journal of molecular sciences, 2023. 24(8): p. 7208.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
